You just read:

Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin

News provided by

Dermata Therapeutics, LLC

Jul 09, 2019, 08:00 ET